Glaucoma surgery studied in medicare patients, new hope for people

July 2, 2008

Ophthalmologists (Eye M.D.s) continue to develop treatments to help the more than three million Americans with glaucoma. The July issue of Ophthalmology includes a large, national study of outcomes of incisional surgeries, used to reduce pressure inside the eye, in Medicare patients. Also covered is research that may brighten the outlook for patients with end-stage glaucoma.

All types of glaucoma damage the disc of the eye's optic nerve, compromise the transmission of images to the brain, and eventually result in blindness if untreated. Intraocular pressure (IOP) is a key measurement taken by eye specialists when screening people for glaucoma; IOP is considered elevated when it measures above 21 millimeters of mercury.

In the United States, primary open-angle glaucoma (POAG) is the most common type. Many other Americans have ocular hypertension (OH), a potential precursor to glaucoma, in which fluid pressure within the eye is elevated but optic nerve damage and/or vision loss have not yet occurred. People of African or Hispanic ethnicity have a higher risk of glaucoma, and African-Americans are more likely to progress to end stage glaucoma.

Large-scale Medicare patient study evaluates glaucoma surgeries

The claims records of 14,491 Medicare beneficiaries diagnosed with glaucoma who received one of three incisional surgeries--- primary trabeculectomy (PT), trabeculectomy in the presence of scarring from previous ocular surgery or trauma (TS), or implantation of a glaucoma drainage device (GDD)---between 1994 and 2003 were analyzed by Frank A. Sloan, PhD, and colleagues. "Incisional" indicates that incisions were used to accomplish the procedure. Similar procedures that use laser tools rather than incisions were not assessed in this study. Surgical treatment may be used when IOP medications become ineffective or other factors make surgery the best option. Because some studies had suggested that performing GDD earlier in complicated glaucoma cases might provide benefit with fewer adverse outcomes, Dr. Sloan's group decided to compare GDD to PT and TS outcomes in a large, national Medicare population.

The three surgeries are designed to improve the drainage of fluid from the eye to reduce IOP. In trabeculectomy (both PT and TS), a small portion of the trabecular meshwork is removed to increase fluid flow, and in GDD a tiny implanted shunt is used to bypass the trabecular meshwork and redirect fluid flow. These incisional techniques have benefitted millions of glaucoma patients who otherwise might be blind or have very low vision.

Study patients were at least 68 years of age but not older than 96 during the period analyzed. A number of important case-mix and demographic factors were controlled for by the study design. Patients' Medicare claim records were analyzed to determine post-surgery rates of severe or less severe outcomes, the need for additional glaucoma-related surgery, or progress to low vision or blindness. Records for follow up at one, two, and when available, six years post-surgery were also analyzed.

The study found that, although adverse outcomes were uncommon for all three surgeries, rates of severe outcomes, less severe outcomes, and progression to low vision or blindness were higher for persons who received GDD than for those who received PT or TS. Also, adverse outcome rates related to trabeculectomy were somewhat higher at six-year follow up than other studies have reported. Patients treated with GDD were more likely to progress to legal blindness. Although the study population was diverse (Medicare patients who represented all areas of the U.S. and a range of ethnicities), the patients treated with GDD were disproportionately African-American, a group at higher risk than other ethnicities of developing glaucoma-related blindness.

This large study demonstrates that most of the differences in outcomes for PT, TS and GDD may be due to disease severity in the patients treated, rather than to differences in the techniques, devices, or surgeons involved in treatment, Dr. Sloan says. "As we move forward, we might expect to see a decrease in complication rates for these surgeries," he concludes.

Hope for patients with end-stage glaucoma---with continued treatment

Doctors can honestly give their end-stage glaucoma patients hope, says a study led by Jason W. Much, M.D. The findings break new ground in an under-researched area and will help Eye M.D.s evaluate, counsel and care for patients with visual field loss due to end-stage glaucoma."Relentless progression to (complete) blindness is not the norm in treated patients," says Dr. Much. "Patients should be encouraged that treatment is not futile. They may retain their visual acuity for many years and be able to perform simple tasks of daily living and enjoy reading and hobbies."

The researchers reviewed charts of 64 patients (84 eyes) with end-stage glaucoma cared for by Eye M.D.s at the University of Pennsylvania Medical Center from 1992 to 2004. All subjects were U.S. residents; most were black and had POAG. At the study baseline, the majority of patients had 20/50 visual acuity or better along with loss of most of their visual field, defined as being able to see less than a 10 degree radius from the center of the eye's focus. Because of the decreased field of vision, these patients were all considered legally blind at the onset of the study.

Fifty-six percent of eyes had had trabeculectomy and 71 percent had had laser trabeculoplasty (removal of part of the trabecular meshwork via laser). The average IOP,controlled by treatment , was 15.36 mmHg throughout the study period. At the study conclusion point, only eight in 84 eyes had 20/200 visual acuity---meaning the ability to see objects clearly and in detail was severely compromised--and in some of these eyes the loss may have resulted from progressive cataract. Few eyes suffered complete blackout of their central visual field because of glaucoma. These findings on maintenance of visual acuity were particularly encouraging in a study population that was predominantly African-American and therefore at higher risk for glaucoma progression.

Source: American Academy of Ophthalmology

Explore further: World's largest clinical specialty database yields critical insights

Related Stories

World's largest clinical specialty database yields critical insights

November 13, 2017
The American Academy of Ophthalmology today announced key milestones and clinical insights from studies powered by its clinical database. The IRIS Registry (Intelligent Research In Sight) has amassed more than 41.2 million ...

Researchers report new paths to glaucoma treatment

September 19, 2017
Researchers at the Center for Vascular Research, within the Institute for Basic Science (IBS), have identified a new mechanism involved in the development and progression of glaucoma, and found a potential therapeutic option ...

Researcher explores best treatments for glaucoma

November 17, 2016
Researchers at Queen's University Belfast together with University of St Andrews and Aberdeen have found that the procedure used to remove cataracts is more successful than current standard treatments with laser in treating ...

Routine glaucoma screening program may benefit middle-age African-American patients

March 12, 2012
Implementing a routine national glaucoma screening program for middle-age African American patients may be clinically effective; however its potential effect on reducing visual impairment and blindness may be modest, according ...

Breakthrough treatment reduces post-surgical scarring for glaucoma patients

July 26, 2012
(Medical Xpress) -- Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

Potential predictor of glaucoma damage identified

May 4, 2017
Glaucoma, a leading cause of blindness worldwide, most often is diagnosed during a routine eye exam. Over time, elevated pressure inside the eye damages the optic nerve, leading to vision loss. Unfortunately, there's no way ...

Recommended for you

Study opens new avenue in quest to develop tuberculosis vaccine

November 24, 2017
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.

Four simple tests could help GPs spot pneumonia and reduce unnecessary antibiotics

November 23, 2017
Testing for fever, high pulse rate, crackly breath sounds, and low oxygen levels could be key to helping GPs distinguish pneumonia from less serious infections, according to a large study published in the European Respiratory ...

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.